

Alfred D Mahr

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3144698/alfred-d-mahr-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155
papers

15,436
citations

64
h-index

123
g-index

168
ext. papers

19,198
ext. citations

6.2
avg, IF

6.06
L-index

#	Paper	IF	Citations
155	Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review.. <i>BMJ Open</i> , 2022 , 12, e050507	3	1
154	Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline.. <i>BMJ, The</i> , 2022 , 376, e064597	5.9	4
153	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 55, 152021	5.3	
152	Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study). <i>Frontiers in Medicine</i> , 2021 , 8, 732934	4.9	1
151	Leptospirosis Followed by Kawasaki-Like Disease: Case Report From an Adult Swiss Patient and Review of the Literature. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab088	1	
150	French recommendations for the management of Behçet disease. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 352	4.2	1
149	Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. <i>Arthritis and Rheumatology</i> , 2021 , 74, 295	9.5	5
148	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1134-1138	5.3	2
147	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. <i>Rheumatology</i> , 2020 , 59, 1187	3.9	
146	International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 ,	10.2	13
145	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020 , 59, 487-494	3.9	27
144	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020 , 59, e1-e23	3.9	57
143	Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records. <i>Lancet Rheumatology, The</i> , 2020 , 2, e774-e778	14.2	7
142	The OMERACT Core Set of Domains for Outcome Measures in Behçet Syndrome. <i>Arthritis Care and Research</i> , 2020 ,	4.7	7
141	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1314-1325	5.3	6
140	Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. <i>Rheumatology</i> , 2020 , 59, 1011-1020	3.9	36
139	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 19-30	2.4	270

138	Characteristics and management of giant cell arteritis in France: a study based on national health insurance claims data. <i>Rheumatology</i> , 2020 , 59, 120-128	3.9	8
137	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1160-1166	2.4	16
136	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019 , 46, 1198-1201	4.1	4
135	Management of skin, mucosa and joint involvement of Behçet syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 752-762	5.3	38
134	Trial of Apremilast for Oral Ulcers in Behçet Syndrome. <i>New England Journal of Medicine</i> , 2019 , 381, 1918-1928	59.2	65
133	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019 , 5, e001003	5.9	26
132	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019 , 5, e001020	5.9	27
131	2018 update of the EULAR recommendations for the management of Behçet syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 808-818	2.4	277
130	Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980-2011). <i>Rheumatology</i> , 2018 , 57, 1047-1055	3.9	24
129	Blue toe syndrome in cutaneous polyarteritis nodosa. <i>Rheumatology</i> , 2018 , 57, 1281	3.9	1
128	Exploring the variability in Behçet disease prevalence: a meta-analytical approach. <i>Rheumatology</i> , 2018 , 57, 185-195	3.9	41
127	Management of major organ involvement of Behçet syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018 , 57, 2200-2212	3.9	57
126	Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders. <i>Autoimmunity Reviews</i> , 2018 , 17, 115-124	13.6	35
125	Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. <i>Arthritis and Rheumatology</i> , 2018 , 70, 171-184	9.5	121
124	Nomenklatur der kutanen Vaskulitiden - deutschsprachige Definitionen des Dermatologischen Anhanges zur Chapel Hill Consensus Conference. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018 , 16, 1425-1433	1.2	6
123	Nomenclature of cutaneous vasculitides - German translation of the dermatologic addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018 , 16, 1425-1432	1.2	9
122	Vaccination and Risk of Childhood IgA Vasculitis. <i>Pediatrics</i> , 2018 , 142,	7.4	7
121	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2018 , 70, 2077-2086	9.5	7

120	Types, frequencies, and burden of nonspecific adverse events of drugs: analysis of randomized placebo-controlled clinical trials. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 731-741	2.6	31
119	Classification des vascularites. <i>Revue Du Rhumatisme Monographies</i> , 2017 , 84, 207-214	0	
118	Incidence of IgA vasculitis in children estimated by four-source capture-recapture analysis: a population-based study. <i>Rheumatology</i> , 2017 , 56, 1358-1366	3.9	46
117	Poor Predictive Value of Isolated Adventitial and Periadventitial Infiltrates in Temporal Artery Biopsies for Diagnosis of Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2017 , 44, 1039-1043	4.1	12
116	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1750-1753	4.1	18
115	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1054-1066	9.5	85
114	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017 , 100, 64-74	11	43
113	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017 , 2, 1018-1031	4.1	17
112	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1933-1937	4.1	25
111	Nonorgan-specific autoantibodies in HIV-infected patients in the HAART era. <i>Medicine (United States)</i> , 2017 , 96, e6230	1.8	12
110	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017 , 3, e000449	5.9	16
109	Dietary and Nondietary Triggers of Oral Ulcer Recurrences in Behçet Disease. <i>Arthritis Care and Research</i> , 2017 , 69, 1429-1436	4.7	18
108	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017 , 44, 1529-1535	4.1	17
107	Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. <i>Rheumatology</i> , 2016 , 55, 1656-63	3.9	38
106	Kawasaki disease in adults: Observations in France and literature review. <i>Autoimmunity Reviews</i> , 2016 , 15, 242-9	13.6	38
105	Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). <i>Revue De Medecine Interne</i> , 2016 , 37, 154-65	0.1	91
104	Reply to: "The relationship between lymphocytic thrombophilic arteritis and cutaneous polyarteritis nodosa". <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, e245-e246	4.5	
103	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1583-94	2.4	628

102	Do vaccinations affect the clinical course of systemic necrotising vasculitis? A prospective observational web-based study. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, S89-92	2.2	7
101	Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the French Vasculitis Study Group. <i>Rheumatology</i> , 2015 , 54, 1970-5	3.9	28
100	Reply: To PMID 24497495. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1408	9.5	
99	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015 , 26, 545-53	3.9	254
98	Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2015 , 30 Suppl 1, i14-22	4.3	127
97	Classification and classification criteria for vasculitis: achievements, limitations and prospects. <i>Current Opinion in Rheumatology</i> , 2015 , 27, 1-9	5.3	25
96	Unified concept for spondyloarthritis and Behçet disease. <i>Nature Reviews Rheumatology</i> , 2015 , 11, 731-40	8.1	124
95	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. <i>Journal of Rheumatology</i> , 2015 , 42, 2436-41	4.1	14
94	Relationship between cutaneous polyarteritis nodosa (cPAN) and macular lymphocytic arteritis (MLA): Blinded histologic assessment of 35 cPAN cases. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 1013-20	4.5	28
93	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015 , 42, 2465-9	4.1	26
92	Gender-specific differences in Adamantiades-Behçet disease manifestations: an analysis of the German registry and meta-analysis of data from the literature. <i>Rheumatology</i> , 2015 , 54, 121-33	3.9	53
91	Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. <i>Rheumatology</i> , 2015 , 54, 471-81	3.9	73
90	Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 177-84	2.4	143
89	Outcomes in critically ill patients with systemic rheumatic disease: a multicenter study. <i>Chest</i> , 2015 , 148, 927-935	5.3	35
88	Noncorticosteroid immunosuppression limits myocardial damage and contractile dysfunction in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). <i>Journal of the American College of Cardiology</i> , 2015 , 65, 103-105	15.1	14
87	Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1117-27	9.5	101
86	Classification and epidemiology of vasculitis 2015 , 1271-1279.e1		
85	Autoimmune diseases in HIV-infected patients: 52 cases and literature review. <i>Autoimmunity Reviews</i> , 2014 , 13, 850-7	13.6	76

84	Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2014 , 371, 1771-80	59.2	573
83	Vocal fold bamboo nodes in undifferentiated connective tissue disease. <i>Rheumatology</i> , 2014 , 53, 1993	3.9	2
82	Brief report: prevalence of antineutrophil cytoplasmic antibodies in infective endocarditis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 1672-7	9.5	67
81	Characteristics, prognosis, and outcomes of cutaneous ischemia and gangrene in systemic necrotizing vasculitides: a retrospective multicenter study. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 681-8	5.3	11
80	INTERNATIONAL CONSENSUS PROJECT: NEURO-BEHÇET DISEASE. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, e4.69-e4	5.5	
79	Epidemiology of primary Sjögren's syndrome in a French multiracial/multiethnic area. <i>Arthritis Care and Research</i> , 2014 , 66, 454-63	4.7	69
78	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 16-23	5.3	81
77	Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. <i>Medicine (United States)</i> , 2014 , 93, 340-349	1.8	82
76	Diagnosis and management of Neuro-Behçet disease: international consensus recommendations. <i>Journal of Neurology</i> , 2014 , 261, 1662-76	5.5	164
75	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013 , 42, 1317-30	2.2	49
74	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1003-10	2.4	141
73	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. <i>Arthritis and Rheumatism</i> , 2013 , 65, 270-81		488
72	L47. Single-organ vasculitis: conceptual and practical considerations. <i>Presse Medicale</i> , 2013 , 42, 628-34	2.2	3
71	ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013 , 27, 45-56	5.3	50
70	Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2457-68		102
69	Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 171-8	5.3	135
68	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3463-71		27
67	Vasculitic emergencies in the intensive care unit: a special focus on cryoglobulinemic vasculitis. <i>Annals of Intensive Care</i> , 2012 , 2, 31	8.9	18

66	Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. <i>Rheumatology</i> , 2012 , 51, 100-9	3.9	217
65	Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 193-200	5.3	40
64	Therapeutic plasma exchange in systemic vasculitis: an update on indications and results. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 261-6	5.3	8
63	Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. <i>Rheumatology</i> , 2012 , 51, 460-7	3.9	105
62	Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. <i>Rheumatology</i> , 2012 , 51, 887-900	3.9	131
61	Sweet syndrome revealing microscopic polyangiitis. <i>Rheumatology</i> , 2012 , 51, 1916-7	3.9	5
60	Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature. <i>Medicine (United States)</i> , 2012 , 91, 67-74	1.8	38
59	Long-term patient survival in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 488-94	2.4	501
58	Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European Vasculitis Study Group clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1415-21	2.4	104
57	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Care and Research</i> , 2011 , 63, 1055-61	4.7	47
56	Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2011 , 63, 863-4		188
55	Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. <i>Arthritis and Rheumatism</i> , 2011 , 63, 1435-45		58
54	Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 704	2.4	80
53	Epidemiology and etiology of Wegener granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and Goodpasture syndrome: vasculitides with frequent lung involvement. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011 , 32, 264-73	3.9	60
52	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 20736-41	11.5	58
51	The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. <i>Medicine (United States)</i> , 2011 , 90, 19-27	1.8	505
50	Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses. <i>Rheumatology</i> , 2011 , 50, 1099-105	3.9	6
49	Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 2381-8	27.4	393

48	Treatment strategies and outcome of induction-refractory Wegener's granulomatosis or microscopic polyangiitis: analysis of 32 patients with first-line induction-refractory disease in the WEGENT trial. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 2125-30	2.4	34
47	Limited value of temporal artery ultrasonography examinations for diagnosis of giant cell arteritis: analysis of 77 subjects. <i>Journal of Rheumatology</i> , 2010 , 37, 2326-30	4.1	37
46	Extraocular manifestations of birdshot chorioretinopathy in 118 French patients. <i>Presse Medicale</i> , 2010 , 39, e97-e102	2.2	13
45	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1744-50	2.4	114
44	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. <i>Arthritis Care and Research</i> , 2010 , 62, 1166-73	4.7	148
43	Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. <i>Arthritis and Rheumatism</i> , 2010 , 62, 616-26		360
42	Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: A prospective randomized study of one hundred twenty-four patients. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1186-97		147
41	Alpha1-antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 3760-7		74
40	Progress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9. <i>Journal of Rheumatology</i> , 2009 , 36, 2362-8	4.1	26
39	Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 103-6	2.4	43
38	HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1287-96		298
37	Epidemiological features of Wegener's granulomatosis and microscopic polyangiitis: two diseases or one anti-neutrophil cytoplasm antibodies-associated vasculitis entity?. <i>Apmis</i> , 2009 , 117, 41-7	3.4	20
36	Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. <i>New England Journal of Medicine</i> , 2008 , 359, 2790-803	59.2	468
35	Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 110-6	2.4	148
34	Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3, 237-52	6.9	73
33	Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1004-10	2.4	273
32	The leukotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. <i>Thorax</i> , 2008 , 63, 677-82	7.3	93
31	Analysis of Wegener's granulomatosis responses to rituximab: current evidence and therapeutic prospects. <i>Clinical Reviews in Allergy and Immunology</i> , 2008 , 34, 65-73	12.3	19

30	Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. <i>Arthritis and Rheumatism</i> , 2008 , 58, 308-17		130
29	Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. <i>Arthritis and Rheumatism</i> , 2008 , 58, 586-94		229
28	Aortic involvement in recent-onset giant cell (temporal) arteritis: a case-control prospective study using helical aortic computed tomodensitometric scan. <i>Arthritis and Rheumatism</i> , 2008 , 59, 670-6		111
27	Assessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 884-91		25
26	Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3951-9		134
25	Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. <i>Annals of the Rheumatic Diseases</i> , 2008 , 67, 1343-6	2.4	62
24	Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. <i>Journal of Rheumatology</i> , 2008 , 35, 1064-72	4.1	80
23	Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis and Rheumatism</i> , 2007 , 57, 686-93		193
22	Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2789-97		343
21	Serum eosinophil cationic protein: a marker of disease activity in Churg-Strauss syndrome. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1107, 392-9	6.5	31
20	Scleroderma renal crisis, still a life-threatening complication. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1108, 249-58	6.5	21
19	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 605-17	2.4	394
18	Long-term outcome of 37 patients with Wegener's granulomatosis with renal involvement. <i>Presse Medicale</i> , 2007 , 36, 771-8	2.2	12
17	Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 222-7	2.4	790
16	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007 , 34, 1357-71	4.1	26
15	Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better?. <i>Annals of the Rheumatic Diseases</i> , 2006 , 65, 826-8	2.4	95
14	Longitudinal cohort study of patients with birdshot chorioretinopathy. I. Baseline clinical characteristics. <i>American Journal of Ophthalmology</i> , 2006 , 141, 135-42	4.9	48
13	Central nervous system involvement in Wegener granulomatosis. <i>Medicine (United States)</i> , 2006 , 85, 53-65		148

12	Seasonal variations in onset of Wegener's granulomatosis: increased in summer?. <i>Journal of Rheumatology</i> , 2006 , 33, 1615-22	4.1	13
11	Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. <i>Medicine (United States)</i> , 2005 , 84, 117-122	1.8	254
10	Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. <i>Medicine (United States)</i> , 2005 , 84, 323-330	1.8	156
9	Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. <i>Medicine (United States)</i> , 2005 , 84, 313-322	1.8	284
8	Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. <i>Annals of Internal Medicine</i> , 2005 , 143, 632-8	8	449
7	ANCA-negative pauci-immune renal vasculitis: histology and outcome. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 1392-9	4.3	121
6	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. <i>Journal of Rheumatology</i> , 2005 , 32, 2488-95	4.1	28
5	Case 36-2003: a woman with impaired renal function. <i>New England Journal of Medicine</i> , 2004 , 350, 1058; author reply 1058	59.2	
4	Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. <i>Arthritis and Rheumatism</i> , 2004 , 51, 92-9		340
3	Predicting mortality in systemic Wegener's granulomatosis: a survival analysis based on 93 patients. <i>Arthritis and Rheumatism</i> , 2004 , 51, 83-91		107
2	Treatment of polyarteritis nodosa and microscopic polyangiitis with poor prognosis factors: a prospective trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in sixty-five patients. <i>Arthritis and Rheumatism</i> , 2003 , 49, 93-100		179
1	Microscopic polyangiitis and polyarteritis nodosa: how and when do they start?. <i>Arthritis and Rheumatism</i> , 2003 , 49, 709-15		95